protein

Recombinant Human Flt-3 Ligand/FLT3L GMP Protein, CF

BT-FT3L-GMP-050

50 ug (also 1 mg)

1348 USD

BT-FT3L-GMP-050

Recombinant Human Flt-3 Ligand/FLT3L GMP Protein, CF

50 ug (also 1 mg)

The Recombinant Human Flt-3 Ligand/FLT3L GMP Protein, CF from R&D Systems is derived from E. coli. The Recombinant Human Flt-3 Ligand/FLT3L GMP Protein, CF has been validated for the following applications: Bioactivity.

Flt-3 Ligand/FLT3L

Proteins and Enzymes

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose.

Unconjugated

97%, by SDS-PAGE with quantitative densitometry by Coomassie« Blue Staining. The molecular weight by mass spectrometry is 17731 Da ▒ 50 Da, with a second mass of 17600 Da ▒ 50 Da also present

Human

17 kDa, under reducing conditions.

18 kDa

Measured in a cell proliferation assay using OCI-AML5 acute myeloid leukemia cells. The ED50 for this effect is 0.200-2.00 ng/mL. The specific activity of Recombinant Human Flt-3 Ligand/FLT3L is 5.00 x 105 units/mg, which is calibrated against the human Flt-3 Ligand WHO standard (NIBSC code: 96/532).

<0.10 EU per 1 ╡g of the protein by the LAL method.

P49771.1

Bioactivity

E. coli -derived human Flt-3 Ligand/FLT3L protein Thr27 - Ala181 Produced using non-animal reagents in an animal-free laboratory. Manufactured and tested under cGMP guidelines.

E. coli

1348 USD

FL, FLG3L, Flt3 ligand, Flt3L, FLT3LG, fms-related tyrosine kinase 3 ligand, SL cytokine

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. A minimum of 12 months when stored at <= -20 ░C as supplied. Refer to lot specific COA for the Use by Date. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, <= -20 ░C under sterile conditions after reconstitution.